Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncodesign Biotechnology has signed a licensing agreement with Janssen Pharmaceutica related to Janssen’s macrocyclic chemistry technology. As per the agreement, Oncodesign will have exclusive access to use the technology in its internal and partnered research programs for six years.
Subscribe to our email newsletter
The technology is expected to be one of the cornerstones of Oncodesign’s integrated drug discovery efforts, together with the in vitro and in vivo translational research capabilities in oncology already established at the company.
Philippe Genne, president and CEO of Oncodesign, said: “This technology is a perfect complement to our well recognized expertise and capabilities in oncology, and most notably to our translational in vivo and ex vivo pharmacology models based on low passage xenografts directly derived from patient tumour material, and allows us to present a unique translational discovery platform to our clients.”
Jan Hoflack, CSO of Oncodesign, said: “Having access to highly potent and selective kinase inhibitors has the potential to transform the use of this therapeutic approach in oncology as well as other therapeutic areas.”